[HTML][HTML] Appropriate antibiotic management of bacterial lower respiratory tract infections

C Feldman, G Richards - F1000Research, 2018 - ncbi.nlm.nih.gov
Lower respiratory tract infections are the leading cause of infectious disease deaths
worldwide and are the fifth leading cause of death overall. This is despite conditions such as …

How can we optimize the diagnostic and therapeutic approach to pneumonia? Expert opinion-based recommendations

M Fernández-Ruiz, JJ Castón, JL Del Pozo… - … y microbiologia clinica …, 2024 - Elsevier
Pneumonia continues to be one of the most frequent infectious syndromes and a relevant
cause of death and health resources utilization. The OPENIN (“Optimización de procesos …

Antibiotic therapy, supportive treatment and management of immunomodulation-inflammation response in community acquired pneumonia: review of …

M Mantero, P Tarsia, A Gramegna, S Henchi… - Multidisciplinary …, 2017 - Springer
Community-acquired pneumonia is a common and serious disease, with high rates of
morbidity and mortality. Management and treatment of community-acquired pneumonia are …

Short-course antibiotic therapy of 5 days in community-acquired pneumonia (CAP5): study protocol for a randomised controlled trial

SB Israelsen, S Tingsgård, L Thorlacius-Ussing… - BMJ open, 2023 - bmjopen.bmj.com
Introduction The optimal duration of antibiotic therapy for community-acquired pneumonia
(CAP) is unsettled. Short-course therapy has proved successful in clinical trials but is not yet …

Short‐course versus long‐course therapy of the same antibiotic for community‐acquired pneumonia in adolescent and adult outpatients

J López‐Alcalde… - Cochrane Database …, 2018 - cochranelibrary.com
Background Community‐acquired pneumonia (CAP) is a lung infection that can be acquired
during day‐to‐day activities in the community (not while receiving care in a hospital) …

¿ Cómo podemos optimizar el abordaje diagnóstico y terapéutico de la neumonía? Recomendaciones basadas en una opinión de expertos

M Fernández-Ruiz, JJ Castón, JL del Pozo… - … y Microbiología Clínica, 2024 - Elsevier
La neumonía es uno de los síndromes infecciosos más frecuentes y una importante causa
de mortalidad y de consumo de recursos. Constituido por expertos en Enfermedades …

Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis

Y Furukawa, Y Luo, S Funada, A Onishi, E Ostinelli… - BMJ open, 2023 - bmjopen.bmj.com
Objectives To find the optimal treatment duration with antibiotics for community-acquired
pneumonia (CAP) in adults. Design Systematic review and duration-effect meta-analysis …

[HTML][HTML] Рациональное использование и оптимальное дозирование антибактериальных препаратов при лечении внебольничной пневмонии

ОА Сиддиков, РМ Нуралиева - Вопросы науки и образования, 2021 - cyberleninka.ru
Пневмония относится к числу наиболее распространенных и актуальных заболеваний
человека, занимая 4-е место в структуре смертности. Риск возникновения пневмонии …

Procalcitonin to reduce exposure to antibiotics and individualise treatment in hospitalised old patients with pneumonia: a randomised study

G Gavazzi, S Drevet, M Debray, JL Bosson, F Tidadini… - BMC geriatrics, 2022 - Springer
Background Treating pneumonia in old patients remains challenging for clinicians.
Moreover, bacterial antimicrobial resistance is a major public health threat. Objective The …

To which extent can we decrease antibiotic duration in critically ill patients?

J Garnacho-Montero… - Expert review of …, 2017 - Taylor & Francis
Introduction: Inadequate empirical antibiotic therapy is associated with higher mortality in
critically ill patients with severe infections. Nevertheless, prolonged duration of antibiotic …